Skip to main content
Clinical Trials/NCT06660641
NCT06660641
Completed
Not Applicable

TaurolockTMHep100 Versus Saline 0.9% As Secondary Prevention of Catheter-related Bloodstream Infections (CRBSI); a Single Center, Double Blinded, Randomized, Controlled Study in Patients with Chronic Intestinal Failure Dependent on Home Parenteral Support (HPS)

Rigshospitalet, Denmark1 site in 1 country61 target enrollmentJune 3, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Catheter Related Blood Stream Infections
Sponsor
Rigshospitalet, Denmark
Enrollment
61
Locations
1
Primary Endpoint
Incidence of recurrent catheter-related bloodstream infections
Status
Completed
Last Updated
last year

Overview

Brief Summary

The purpose of the trial is to compare two catheter lock solutions (active: 1.35% taurolidine and placebo: 0.9% saline), on the occurence of catheter related blood stream infection, in patients with intestinal failure and a central venous catheter for home parenteral support.

Detailed Description

Patients with long-term intestinal failure rely on Home Parenteral support (HPS) delivered through a central venous catheter(CVC). Catheter Related Blood Stream Infections(CRBSI) are a frequent complication leading to increased morbidity, hospital admissions, cost, and risk of repeated replacement of the CVC. The infections often originate from contamination of the catheter hub, and growth of microorganisms on the inner lumen of the catheter imbedded in a biofilm. To prevent infections good hygiene guidelines and the use of a catheter lock solution is applied. The primary objective is to compare two catheter lock solutions, 1,35% taurolidine and 0.9% saline, on the occurence of recurrent CRBSIs. The secondary objectives are to compare the two devices according to other catheter-related complications, adverse events and costs. Patients with at least one prior CRBSI is included. Patients instill the solution in their CVC after each infusion of HPS, with a minimum of three times per week, depending on their individual HPS programme. Before the blinded randomization the patients will be paired according to age and stratified according to prior CRBSI incidence. Duration of the instillation will be 24 months.

Registry
clinicaltrials.gov
Start Date
June 3, 2019
End Date
February 28, 2022
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Palle Bekker Jeppesen

MD, PhD, DMSc, Professor

Rigshospitalet, Denmark

Eligibility Criteria

Inclusion Criteria

  • Patients receiving HPS at the department of Medical gastroenterology, Rigshospitalet, who have at least one prior CRBSI and thereby demonstrated susceptibility towards developing CRBSI while on HPS and the following:
  • Signed informed consent form
  • Has a single-lumen subcutaneously tunneled CVC
  • Has been at least 3 weeks since termination of the antibiotic treatment for their last CRBSI

Exclusion Criteria

  • Patients who:
  • have a known hypersensitivity/allergy to TauroLockTMHep 100 or heparin and/or their excipients
  • are pregnant, lactating or nursing

Outcomes

Primary Outcomes

Incidence of recurrent catheter-related bloodstream infections

Time Frame: Treatment time 2 years

Study Sites (1)

Loading locations...

Similar Trials